A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
ATRC-101-A01 is a Phase 1b, open-label dose escalation trial of ATRC-101, an engineered fully
human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human
antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will be
characterized when administered every two weeks (Q2W) or every 3 weeks (Q3W) as a monotherapy
or in combination with other anticancer agents.